MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.33
-0.03
-0.56%
Closed 16:00 09/24 EDT
OPEN
5.29
PREV CLOSE
5.36
HIGH
5.37
LOW
5.20
VOLUME
207.36K
TURNOVER
--
52 WEEK HIGH
13.81
52 WEEK LOW
3.680
MARKET CAP
90.06M
P/E (TTM)
-0.8467
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 6d ago
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire's Inducement Plan as a material inducement to one ...
GlobeNewswire · 09/03 21:00
Ocuphire Pharma Presenting at Four Conferences in September
Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021 Cantor Virtual G...
GlobeNewswire · 09/02 11:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 08/13 22:07
Ocuphire Pharma EPS misses by $0.08
Ocuphire Pharma (NASDAQ:OCUP): Q2 GAAP EPS of -$0.52 misses by $0.08. Revenue of $0.1M. As of June 30, 2021, the Company had cash and cash equivalents of approximately $24.2 million.
Seekingalpha · 08/12 11:45
BRIEF-Ocuphire Announces Q2 Loss Per Share Of $0.52
reuters.com · 08/12 11:34
Ocuphire Pharma Q2 EPS $(0.52) Down From $(0.43) YoY
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.52) per share. This is a 20.93 percent decrease over losses of $(0.43) per share from the same period last year.
Benzinga · 08/12 11:32
-- Earnings Flash (OCUP) OCUPHIRE PHARMA Reports Q2 Revenue $100,000
MT Newswires · 08/12 07:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCUP. Analyze the recent business situations of Ocuphire Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCUP stock price target is 25.75 with a high estimate of 29.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 1.07M
% Owned: 6.33%
Shares Outstanding: 16.90M
TypeInstitutionsShares
Increased
7
90.99K
New
14
614.86K
Decreased
2
80.09K
Sold Out
5
469.45K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Cam Gallagher
President/Chief Executive Officer/Vice Chairman/Treasurer/Director
Mina Sooch
Chief Accounting Officer/Vice President - Finance
Amy Rabourn
Lead Director/Independent Director
Sean Ainsworth
Director
Susan Benton
Director
James Manuso
Director
Jay Pepose
Independent Director
Richard Rodgers
No Data
  • All
  • Financials
  • Insiders
More
About OCUP
Ocuphire Pharma, Inc., formerly Rexahn Pharmaceuticals, Inc., is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. Its lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically induced mydriasis (RM) and presbyopia. Its second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Its pre-clinical product candidates are APX2009 and APX2014.

Webull offers kinds of Ocuphire Pharma Inc stock information, including NASDAQ:OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.